Background: Adaptive Biotechnologies has built an immune medicine platform based on the sequencing of immune receptors (immunoglobulins, B-cell receptors [BCRs] and T-cell receptors [TCRs]) with myriad applications in health and disease. This broad platform technology can be used to assess the diversity of the cellular adaptive immune system and track disease-associated TCRs and BCRs during the course of infection. The SARS-CoV-2 virus is spreading rapidly throughout the world, causing significant morbidity and mortality. Researchers, governments, and biotechnology companies are mobilizing to develop and distribute diagnostic and therapeutic alternatives to try to curb this global pandemic. Methods: In collaboration with our partners LabCorp/Covance, Adaptive Biotechnologies has opened the ImmuneRACE study to prospectively collect samples from individuals who have been infected with SARS-CoV-2, who have recovered from SARS-CoV-2 infection, or who have been exposed to someone infected with SARS-CoV-2. Discussion: We believe that the information contained within the genetics of the adaptive immune response to SARS-CoV-2 can improve our understanding of the immunobiology of this devasting virus and may inform efforts to improve current diagnostic and therapeutic approaches. To facilitate scientific and clinical advancement in the fight against COVID-19, the TCR sequence data resulting from the primary aims of this study will be made publicly available to scientists and researchers across the globe, an effort made possible through a collaboration with Microsoft. Trial registration: ImmuneRACE is registered with the US National Institutes of Health and can be accessed at ClinicalTrials.gov (NCT04494893).

中文翻译：

---

ImmuneRACE研究：使用ImmuneCODE™开放访问数据库对COVID-19事件的免疫应答行动进行的前瞻性多队列研究

背景：适应性生物技术公司已经建立了基于免疫受体（免疫球蛋白，B细胞受体[BCR]和T细胞受体[TCR]）测序的免疫医学平台，在健康和疾病领域有无数的应用。这种广泛的平台技术可用于评估细胞适应性免疫系统的多样性，并在感染过程中跟踪与疾病相关的TCR和BCR。SARS-CoV-2病毒正在世界范围内迅速传播，从而导致高发病率和高死亡率。研究人员，政府和生物技术公司正在动员开发和分发诊断和治疗替代品，以试图遏制这种全球性流行病。方法：与我们的合作伙伴LabCorp / Covance合作，Adaptive Biotechnologies已启动ImmuneRACE研究，以前瞻性地收集感染SARS-CoV-2感染者，从SARS-CoV-2感染中恢复过来或暴露于SARS-CoV-2感染者的样本。讨论：我们认为，对SARS-CoV-2的适应性免疫应答的遗传学内所包含的信息可以增进我们对这种毁灭性病毒的免疫生物学的了解，并可能有助于改进当前的诊断和治疗方法。为了促进抗COVID-19的科学和临床进步，将通过本研究的主要目的而获得的TCR序列数据将公开提供给全球的科学家和研究人员，这是通过与Microsoft的合作而实现的。试用注册：